The global Virtual Screening Service market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Virtual screening service is a process in which computer algorithms and software are used to screen large databases of chemical compounds or molecules in order to identify potential drug candidates or molecules with desired properties. It is a cost-effective and time-efficient method for drug discovery and development.

Virtual screening service involves the use of computational models and algorithms to predict the biological activity, pharmacokinetics, and toxicity of compounds. It can be used to identify potential drug targets, optimize lead compounds, and prioritize compounds for further experimental testing.

The process typically involves the following steps:

1. Database preparation: The chemical database is prepared by converting the compounds into a suitable format for virtual screening.

2. Target selection: The specific target or protein of interest is selected for screening. This could be a disease-related protein, enzyme, receptor, or any other biological target.

3. Ligand-based or structure-based screening: Virtual screening can be performed using ligand-based or structure-based methods. Ligand-based methods use known active compounds as references to identify similar compounds in the database. Structure-based methods involve docking the compounds into the target proteins binding site to predict their binding affinity.

4. Scoring and ranking: The screened compounds are scored and ranked based on their predicted activity, binding affinity, or other desired properties. The top-ranked compounds are considered as potential drug candidates.

5. Experimental validation: The selected compounds are further tested in vitro or in vivo to validate their activity and properties. This step involves laboratory experiments and can lead to the identification of lead compounds for further development.

Virtual screening service has become an integral part of the drug discovery process, as it allows researchers to quickly screen large chemical databases and identify potential drug candidates with reduced time and cost compared to traditional experimental screening methods.

United States market for Virtual Screening Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Virtual Screening Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Virtual Screening Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Virtual Screening Service players cover Profacgen, CD ComputaBio, Creative Biolabs, BOC Sciences, Jubilant Biosys, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

Infinity Market Research newest research report, the ?Virtual Screening Service Industry Forecast? looks at past sales and reviews total world Virtual Screening Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Virtual Screening Service sales for 2025 through 2031. With Virtual Screening Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Virtual Screening Service industry.

This Insight Report provides a comprehensive analysis of the global Virtual Screening Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Virtual Screening Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Virtual Screening Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Virtual Screening Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Virtual Screening Service.

This report presents a comprehensive overview, market shares, and growth opportunities of Virtual Screening Service market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Structure-based Virtual Screening (SBVS)
    Ligand-based Virtual Screening (LBVS)
    Others

Segmentation by Application:

    Drug Discovery
    Materials Science
    Toxicology
    Molecular Modeling

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Profacgen
    CD ComputaBio
    Creative Biolabs
    BOC Sciences
    Jubilant Biosys
    MedChemExpress (MCE)
    HitGen
    TargetMol Chemicals
    WuXi AppTec
    LeadBuilder - Domainex
    CSNpharm
    ChemNavigator
    CKTTDB
    Molinspiration
    Molsoft
    Southwest Research Institute